Delivery Order SPE2DR25D1004-SPE2DR26FSVT5
Award Date 12/1/25
Potential Completion Date 12/2/25
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $10,437.46 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on December 1, 2025, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $6,558.40 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 25, 2025, with completion by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $15,558.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the...
- The Defense Logistics Agency awarded a $124,232.78 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 31, 2025, with an ultimate completion date of November 3, 2025. The award was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $5,137.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on October 17, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a $3,279.20 delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit of use packaging). This is a firm fixed-price, non-set-aside competitive award with a completion date of December 12, 2025, to be performed at the contractor's Conshohocken, Pennsylvania location. RINVOQ (upadacitinib) is a Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $14,983.48 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on May 30, 2025, with a completion date of June 2, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $9,468.86 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count packaging) on December 10, 2025, with completion scheduled for December 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...